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Abstract
Background: Paediatric palliative care (PPC) aim to ensure the control of symptoms and the best possible quality
of life for patients whose underlying disease, characterized by an unstoppable evolution and negative prognosis, no
longer responds to specific treatments. The scientific evidence in this context are very deficient and, in order to obtain
welfare objectives consistent with the situation, in the overwhelming majority of cases the prescription of drugs is off-label
for indication of use and/or for age and/or for way of administration and/or formulation.
The Agenzia Italiana del Farmaco - AIFA and the Italian Society of Palliative Care (Società Italiana di Cure Palliative - SICP),
under a dedicated working group, wrote a document that collects the scientific evidence available to support the off-label
use of medicines more frequently used in PPC. The goal is to certify the consolidated off-label use of these drugs and
propose their use under the Law 648/96, in the absence of data from its pivotal clinical trials.
Aim of the commentary is to report the conditions for this important work and to present the 10 drugs, usually used
off-label in PPC and in pain therapy, now included in Law 648/96.
Conclusion: This work is deemed essential to resolve, at least in part, the lack of availability of medicines researched
and approved.
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Introduction
Off-label use of drugs in pediatrics
On January 26th 2007, the European Regulation on
medicinal products for paediatric use (Regulation EC
No 1901/2006) [1] entered into force in all the European
Union countries. The aims of this regulation are to facilitate
the development and the accessibility to medications specif-
ically designed for children from 0 to 18 years old, to ensure
that medicinal products used in paediatric population are
subject to high quality ethical research and appropriately
authorized for use in children, as well as to increase the in-
formations availability on use of medicines for children [2].
However despite the European Regulation and initiatives
put forward in this area by Agenzia Italiana del Farmaco
(AIFA), still only one third of drugs available to the adult
range gets to the pediatric patient and sometimes only
after many years. The analysis of the current situation
shows that many new drugs and most molecules already
available since long time on the market, are not registered
for pediatric use.
It follows that, in clinical practice, children are often
treated with medications designed and tested only in
the adults, according to procedures and indications not
specifically envisaged nor registered for children (off-label
use of the drug). Using a drug off-label means prescribing
it in conditions that differ from those for which it has
been authorized, in terms of age, dosage regimen (dose or
frequency of administration), therapeutic indication, route
of administration and formulation.
The off-label and unlicensed classification methods
varied, making results difficult to compare [3–5]. Many
studies reported high rates of off-label (9 to 78.7%) and
unlicensed (0.3 to 35%) drug use in different pediatric
patient settings [5]. The extent of paediatric unlicensed/off
label use is higher in neonatal and paediatric intensive care
units and oncology wards, compared with primary care
[4]. On the paediatric hospital wards, off-label/unlicensed
prescriptions ranged from 16 to 62% [3]. In the neonatal
wards, rates ranged from 55 to 80% [3]. In the community
setting, rates ranged from 11 to 37% [3].
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This lack of adequate registration is caused by different
issues:
– There are problems of numerosity and heterogeneity
of patients and clinical situations: between 0 and
18 years there are at least three different
sub-populations (infants, children and adolescents) with
biological and metabolic characteristics significantly
different from each other, and therefore requiring
specific studies and experiments [6].
– There are ethical issues: there is in fact a kind of
ethical bias to expose children to experimental
clinics, although, on the contrary, this may go to
harm their own interests, since it precludes the
possibility of developing drugs tailored to their
specific needs [7].
– .There are finally economic reasons determined by
the costs of the trials and the limited economic
return: a situation that discourages investment by
the pharmaceutical industry.
Since publication of the 2002 statement from the
American Academy of Pediatrics on the off-label use of
drugs [8], the number of drugs approved with pediatric
indications or expanded labeling that informs drug use
in pediatric patients has substantially increased [9–11].
However, despite this success and advances in both basic
science and clinical trials in pediatrics, off-label drug use
remains a common and important issue for children and
adolescents [12].
Off-label use is in many situations the only therapeutic
option [12–14]. Such use has in clinical practice a “crucial”
and, in many situations, not deferrable role and, although
unauthorized, has frequently long periods of pediatric use
(clinical practice statement), as well as studies and reports
in the literature that strongly support drug efficiency and
safety [12, 14].
Remarkably off-label prescription has clinical, legal
and ethical implications to consider [12] the chance of
making mistakes in the definition of a treatment is
greater, it involves the direct assumption of responsibility
by the prescriber (both in terms of efficacy and possible
adverse effects), it requires informed consent by a person
conducting the parental authority and has an impact on
drug reimbursement.
The issue of the off-label use of drugs in Pediatrics is
further amplified in certain areas, where even more
problems related to the difficulty of developing clinical
trials for specific type of patients, features of situations
and/or newness of the problema may arise [12, 15]. For
example, these critical issues are greater in neonatology,
in rare and complex diseases, in children with life threat-
ening/limiting disease and/or in terminal illness, where
trials are rarely conducted both for the low numerosity
and high heterogeneity of the population, both for ethical
reasons and sometimes for lack of economic resources.
The result is that the off-label use of drugs in these
conditions represents the standard of treatment, con-
solidated and time honoured in the management of the
young patient. In these areas the treatment choices are
made on the basis of an established practice, often deduced
from experience/studies completed in adults, and limited
pediatric specific evidence. This is the case of pediatric
palliative care [16].
Pediatric palliative care
In recent years, a slow but continuous change of the
care needs of the ill infant/child/adolescent took place:
new types of patients, new situations and new goals of
“health”. Certainly one of these new fields is represented
by the needs of Palliative care in the pediatric population.
Pediatric Palliative Care (PPC) are that part of pediatric
medicine that takes care of children with incurable disease
and/or severe disabilities: the goal of palliative care is the
quality of young patient’s life and symptom control [17].
Home is, in the vast majority of cases, the chosen and
ideal place for care and treatment. The spectrum of
diseases potentially eligible at PPC is heterogeneous
and broad (neurological diseases, oncology, cardiology,
respiratory, muscular, metabolic, infectious, developmental
disorders, chromosomal, post anoxic) and heterogeneous
and large is also the spectrum of needs, clinical and not,
that they trigger, and the modality needed for the care of
the patient. It is estimated that in Italy children eligible to
PPC are about 30,000 [18].
The main goal for all these children is alleviating
suffering and pain, while addressing and containing all
the other stressful symptoms and conditions. In these
contexts the scientific evidence are scant and, in order
to obtain welfare objectives consistent with the situation,
the prescription of drugs is off-label in the overwhelming
majority of cases, for indication use and/or for age and/or
modality of administration and/or formulation [19]. Minors
eligible at PPC are patients at high-complexity of assistance,
affected by multiple pathologies which trigger complex
symptoms that require polytherapy, frequently for long
periods of time.
These are often patients with complex conditions which
may limit the possibility of assuming drugs through routine
routes of administration, requiring alternative ways such as
the intranasal, the submucosal, the inhalatory one. Often
these children may have cognitive and/or relational deficits
which limit the possibility for sharing, actively participate
or accept the management of a treatment plan.
In the majority of cases, the management of these infants/
children/teenagers takes place at home and thus the medica-
tion management is settled into a different contest from that
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Table 1 The 10 drugs singled out for an authorised “off-label” use in PPC
Drug On-label use Authorized l. 648/96
off-label use
Advised dosage
HYOSCINA
BUTYLBROMIDE
Pill in child > 14 years, supp in child
> 6 years: spastic– painful events of
urinary and genital tract.
1. Iv administration for intestinal
obstruction due to peritonitis in pediatric
patients with cancer.
2. Iv administration for reduction of
secretions and rattle in terminally ill
patient.
Iv: Child 1 month-4 years:
300–500 micrograms/Kg
3–4 times a day (max. Per dose 5 mg)
Child 5–11 years: 5–10 mg 3–4 times a day
Child 12–17 years:10–20mg 3–4 times
a day [24]
DEXMEDETOMIDINE Procedural analgo-sedation outside the
operating room (Not Operating Room
Anesthesia - NORA) in children with
difficult airway management and child
with seizure disorders who must
undergo diagnostic studies for locating
epileptogenic foci
Analgo-sedation of critical infant and
child in ICU, mechanically ventilated
and poorly responsive to conventional
analgo-sedation treatment.
1. Control of stressful symptoms from
disease or procedure and fix sleep
outside the ICU in patients in palliative
care, not responsive to conventional
therapies.
2. Intranasal route of administration.
Iv: 1 mcg/kg in a 10-min bolus, increased
up to a maximum of 3 mcg/kg, and
followed by a 1 mcg/kg/h infusion [25]
In: 1 to 4 mcg/kg, eventually
re-administered at 1 mcg/Kg [25]
FENTANYL Premedication for any type of
anesthesia (also local) both in the
postoperative period as during surgery.
1. Transdermal, iv use for acute and/or
chronic pain management from cancer
and not, in children in PPC.
2. Transmucosal use for procedural/
acute/breakthrough pain in PPC.
Transdermal: based on oral morphine
dose equivalent (given at 24-h totals).
Product monograph: oral morphine
45 mg = 12 mcg/h patch oral morphine
< 90 mg = 25 mcg/h patch oral morphine
135–189mg = 50 mcg/h patch oral
morphine 225–314mg= 75 mcg/h patch [26]
Iv: Child > 6months and < 50 Kg:
bolus 0,5–1 mcg/Kg every 1–2 h, dose to
be administered over at least 30 s; infusion
0,5–2 mcg/Kg/h
Child > 50 Kg: bolus 25–50 mcg every
1–2 h, dose to be administered over at
least 30 s; infusion 25–200 mcg/h [27]
Transmucosal: Child 2–18 years and
weiting > 10 Kg: 15–20 mcg/Kg as a single
dose, titrated to a maximum dose of
400 mcg [26]
GABAPENTIN Pill in child > 6 years: adjunctive
therapy in the treatment of partial
seizures in the presence or absence of
secondary generalization.
> 12 years: monotherapy in the
treatment of partial seizures in the
presence or absence of secondary
generalization
Neuropathic or mixed pain in children
older than 2 years in palliative care.
By mouth: Child > 2 years:
Day 1: 10 mg/Kg (maximum single dose
300mg)
Day 2: 10 mg/Kg twice daily
Day 3 onwards: 10 mg/Kg 3 times daily
Increase further if necessary to a maximum
of 20mg/Kg/dose (maximum single
dose 600 g)
Child > 12 years:
The maximum daily dose can be increased
according to responde, up to e a
maximum of 3600mg/day [26]
KETAMINE Im, iv and continuous infusion
administering
Use for induction and maintenance of
general anesthesia from neonatal and
premedication in children older
than1 month.
1.Use in patients in PPC for managing
procedural or mixed/neuropathic pain
that does not respond to other therapy,
alone or in combination/replacement for
opioid analgesics.
2. Intranasal administration
Im: Neonate: 4 mg/Kg, adjusted according
to response, a dose of 4 mg/Kg usually
produces 15 min of surgical anaesthesia
Child: 4–13 mg/Kg, adjusted according to
response, a dose of 4 mg/Kg sufficient for
some diagnostic procedures, a dose of
10 mg/Kg usually produces 12–25 min of
surgical anaesthesia [24]
Iv for short procedures: Neonate:
1–2mg/Kg, adjusted according to response,
to be given over at least 60 s, a dose of
1–2mg/Kg produces 5-1o minutes of
surgical anaesthesia
Child 1 month-11 years: 1–2 mg/Kg,
adjusted according to response, to be
given over at least 60 s, a dose of
1–2 mg/Kg produces 5-1o minutes
of surgical
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Table 1 The 10 drugs singled out for an authorised “off-label” use in PPC (Continued)
Drug On-label use Authorized l. 648/96
off-label use
Advised dosage
Child 12–17 years: 1–4,5 mg/Kg, adjusted
according to response, to be given over
at least 60 s, a dose of 2 mg/Kg usually
produces 5-1o minutes of surgical [24]
Continuous Iv Infusion:
Child 1 month-17 years: starting dose
40 mcg/Kg/h., increase according to
response, usual maximum dose is
100 mcg/Kg/h [26]
Intranasal: Child 1 month-17 years:
0,5–10mg/kg/dose, start with lower dose
and increase according to response [28–31]
KETOROLAC The safety and efficacy in children has
not been established. The use of the
drug is therefore contraindicated
below 16 years.
Pill and drop: used to treat short term
(max 5 days) of moderate
postoperative pain.
Iv/im: indicated in the short term
treatment (maximum two days) for
moderate-severe postoperative pain.
By mouth/im use for treatment of
acute pain starting from 16 years of
life, iv from 6months.
By mouth and sublingual use for
chidlren 4–15 years old, for a maximum
period of 5 days, in patients receiving
PPC without vascular access, for
management of moderate/severe acute
episodic nociceptive pain, which
integrate other analgesia if not effective,
in the course of pathology eligible to
PPC or in terminall illness.
Iv: Child 6 months-15 years: initially
0,5–1 mg/Kg (max. Per dose 15 mg), than
500 mcg/Kg every 6 h (max. Per dose
15 mg) as required for maximum duration
of treatment 2 days; maximum 60mg
per day [24]
Im e Iv: Child 16–17 years (body-weight
up to 50 Kg): initially 10 mg, than
10–30 mg every 4–6 h as required for
maximum duration of treatment 2 days,
maximum 60mg per day
Child 16–17 years (body-weight 50 Kg and
above): initially 10 mg, than 10–30mg
every 4–6 h as required for maximum
duration of treatment 2 days, maximum
90mg per day [24]
By mouth/sublingual: Child 4–15 years:
0,5 mg/Kg/ dose, maximum 3 doses/day
for maximum duration of treatment
5 days [32]
LIDOCAINE Peripheral and regional anesthesia,
surgical stomatology.
1.Nebulized use for the treatment of
cough refractory to other therapies, if
pulmonary metastases
2. Intravenous use to treat neuropathic
pain in patients in PPC not responsive
to conventional therapies.
Nebulized: 5 ml of 0,2% solution every
8 h [33]
Iv: 10–15 mcg/Kg/min [34]
MIDAZOLAM Iv: conscious sedation before and
during diagnostic or therapeutic
procedures with or without local
anaesthesia; Anesthesia: Premedication
before induction of anesthesia;
Sedation in ICU.
Children 3 months-18 years: treatment
of acute prolonged seizures
Children > 1month: treatment of
status epilepticus or following crises
1. Intranasal use due to less invasiveness
and high speed of administration in the
absence of venous access, even in
urgent cases in patients aged over
1 month in PPC.
2. Intravenous use to manage
non-painful distress symptoms
during end of life.
Intranasal: 0,2–0,5 mg/Kg/dose [35, 36]
Iv: Child 1 month-17 years:
0,05–0,3 mg/Kg/h [26]
ONDANSETRON Pill, syrup, vial in children ≥6 months
to control chemotherapy-induced
nausea and vomiting (CINV).
Vial in children ≥1 month for
prevention and treatment of
post-operative nausea and
vomiting (PONV).
Control of nausea and vomiting
during opioid therapy in patients
aged > 6 months in palliative care
Iv: Child 1–12 years: 5 mg/m2 (maximum
single dose 8 mg) every 8–12 h
Child 12–17 years: 8 mg every 8–12 h [26]
By mouth
Child 6 months-17 years (BSA up to 0.6 m2):
2 mg every 12 h for up to 5 days (dose can
be started 12 h after iv administration);
maximum 32mg per day.
Child 6 months-17 years (BSA 0.6–1.2 m2):
4 mg every 12 h for up to 5 days (dose can
be started 12 h after iv administration);
maximum 32mg per day.
Child 6 months-17 years (BSA 1.3 m2 and
above): 8 mg every 12 h for up to 5 days
(dose can be started 12 h after iv
administration); maximum 32mg
per day [24]
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of a hospital or outpatient setting, with different standards
of recording and monitoring.
Off-label drugs and law 648/96
In Italy, the off-label use is governed by Law 648/96 that
has identified a list of medications with a therapeutic
indication other than that authorised, used in clinical
practice for consolidated use and data from scientific
literature. These drugs, once inserted in the list of medi-
cinal products established by Law 648/96, are adminis-
tered under the physician’s direct responsibility and can
be reimbursed by the National Health Service [20].
In this list, there are drugs partially covering the needs
of different areas of pediatric medicine such as drug
listed for oncological, cardiovascular [21], gastrointestinal,
anesthetics [22], anti-infective, dermatological, genitouri-
nary tract medications and hormones.
This list lacks of some medicines frequently used to
control pain and other relevant symptoms in the PPC.
Given the peculiar situations and cure aims that PPC
promise, we identified a list of medications used in the
PPC for which inclusion in the list established by Law
648/96, represents for patients, operators and all the
health system a goal of efficacy, safety and equity.
For using such drugs, it remains mandatory to collect,
by the legal representatives of the child, the informed
consent at use. It’s also important to inform the child,
with tool and modality appropriate to age, clinical situ-
ation and capacity of discernment, on medication and
strategies of administration, in the perspective of sharing
and participating to the treatment program.
Aims
A list of drugs used off-label in pediatric palliative care
(PPC) and in pain therapy, deemed essential to solve, at
least in part, the low availability of medicinal products
studied and approved in pediatric age, has been filled out.
Ten drugs have been identified that routinely, for specific
indications in PPC clinical practice, are used off-label with
modality that are different from those for which they have
been authorized in terms of age, dosage, therapeutic indi-
cation, route of administration and formulation.
In order to derive a proposal for inclusion in the list of
medications dispensed in accordance with law 648/96,
the work includes information about the scientific evidence
to support the off-label use (literature, RCT, any clinical
studies in course) and the use of the active ingredient in
the off-label indication in other Member States (United
Kingdom, with reference to the British National Formulary,
BNF for children, Edition 2016–17).
The list has the aim to indicate the active ingredients,
for each ATC class, which can be used in children under
the CPP, although their use is not approved in childhood.
For some of them, there is a rational use as supported by
available evidence, even in the absence of controlled trials,
frequently in case of old molecules or for objective diffi-
culties in conducting pediatric clinical trial.
Some indications applied for inclusion in the list according
to Law 648/96, refer to therapies that are used for short
periods of time, in the course of exacerbations and/or
end-of-life. Other requests instead, refer to prolonged
use (months, years), during the course of taking charge
in palliative care of the child with an incurable disease.
For each of the 10 identified active ingredients a single
card was formalized that lists the specific indication of
on-label demand in clinical practice, the rationale of the
request, the evidence in support of the request, the
current situation that is approved for use from leaflet,
any additional notes [23]. The drugs detected are listed
in Table 1.
Conclusions
The Agenzia Italiana del Farmaco (AIFA) and the Italian
Society of Palliative Care (SICP), under the dedicated
work table, drew up a document that gathers the scientific
evidence available to support the off-label use of medicines
more frequently used in the field of pediatric palliative
care, with the goal of attesting to the off-label use of these
drugs and propose their use under the law 648/96, in the
absence of data from clinical trials.
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Table 1 The 10 drugs singled out for an authorised “off-label” use in PPC (Continued)
Drug On-label use Authorized l. 648/96
off-label use
Advised dosage
SCOPOLAMINE Not marketed in Italy Treatment of hypersalivation in
patients in palliative care and end
of life by transdermal route.
Neonate: quarter of a patch every 72 h
Child 1 month to 3 years: quarter of a
patch every 72 h
Child 3–10 years: half a patch every 72 h
Child 11–17 years: one patch every 72 h [26]
Abbreviation: Iv Intravenous, In Intranasal, Im Intramuscular, BSA Body surface area, ICU Intensive Care Unit, PPC Pediatric Palliative Care
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